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Cystic fibrosis (CF) is a genetic disease caused by mutations in the CF transmembrane
conductance regulator (CFTR) gene, resulting in defective ion transport in the airways.
Addition of a functioning CFTR gene into affected airway cells has the potential to be an
effective treatment for lung disease. The therapeutic efficacy of airway gene transfer
can be quantified in animal models by assessing ion transport in the treated nasal
epithelium using the nasal potential difference (PD) measurement technique. The nasal
PD technique is routinely used in CF mice, however when applied to a recently
developed CF rat model those animals did not tolerate the initial nasal PD
assessment, therefore the procedure was firstly optimised in rats. This study
evaluated the effect of lentiviral (LV)-mediated CFTR airway gene delivery on nasal
PD in a CFTR knockout rat model. LV gene vector containing the CFTR gene tagged
with a V5 epitope tag (LV-V5-CFTR) was delivered to the nasal epithelium of CF rats,
and one week later nasal PD was analysed. This study demonstrated for the first time
that LV-V5-CFTR treatment produced a mean correction of 46% towards wild-type
chloride response in treated CF rats. Transduced cells were subsequently identifiable
using V5 immunohistochemical staining. These findings in the nose validate the use of
airway gene therapy for future lung based experiments.
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INTRODUCTION
Cystic fibrosis (CF) is a common, life-shortening, recessive genetic disorder, resulting from mutations in
the cystic fibrosis transmembrane conductance regulator (CFTR) gene (Davis, 2006). CF affects multiple
organs and despite symptomatic treatments and CFTRmodulator therapies that improve quality of life it
remains incurable, with lung disease the major cause of mortality (Carlon et al., 2017). The
pathophysiology of CF results from a loss of CFTR chloride channel function and via its interaction
with other ion channels such as the epithelial sodium channel (ENaC). Together these channels regulate
chloride and sodium ionmovement across the epithelial surface of many organs, maintaining osmolarity.
In CF airways an imbalance of these ions creates altered movement of water, causing the mucus layer
lining the airways to become dehydrated and vicious. The resulting viscous mucus is thick, difficult to
clear, and the ideal environment for bacteria and other pathogens to grow. Thus, CF airways experience a
continuous cycle of infection and inflammation, leading to permanent lung damage and ultimately
respiratory failure (Chmiel et al., 2002).
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Correcting CFTR dysfunction at the genetic level, by the
addition of a functioning CFTR gene into affected airway cells,
has the potential to be an effective treatment for CF lung disease.
As CF is monogenic, addition of one correct copy of the CFTR
gene into the cells should be sufficient to halt disease or prevent it
if initiated early in life (Villate-Beitia et al., 2017). A range of viral
and non-viral vectors can be used to facilitate the transfer of a
gene to the airway epithelial cells. Lentiviral vectors (LV) are
attractive vehicles as they can transduce dividing and non-
dividing cells, integrate into the host genome providing long
term expression, and generate little immune response (Castellani
and Conese, 2010).
Our group has utilised a vesicular stomatitis virus type G
(VSV-G) pseudotyped LV vector and two-step dosing procedure
that involves conditioning the airways with
lysophosphatidylcholine (LPC) prior to vector delivery. Using
this approach, we have shown that nasal delivery of LV-CFTR can
successfully correct CFTR function in a CFmousemodel for up to
12 months after a single dose, and improves survival of the treated
animals (Cmielewski et al., 2014). The nasal airway region is used
because the ion transport defects in the CF mouse nasal airway
epithelium closely resemble those of the human CF lung (Ferrari
et al., 2002). Additionally, the nasal cavity is easily accessed,
which makes it a suitable site to test ion transport function as a
representation of the lower airways (Rowe et al., 2011). CF mouse
models have predominantly been used in CF research, however
they do not exhibit the human lung pathophysiology, so further
lung investigations can be limited (McCarron et al., 2018;
McCarron et al., 2020).
Nasal PD has been used as a CF diagnostic method in
humans for over 25 years, as it is well tolerated (Knowles et al.,
1981). It has been adapted for use in some CF animal models,
particularly mice, to test the efficacy of various therapeutic
strategies. A CFTR knockout (KO) rat model was recently
developed by CRISPR/Cas9 gene editing as an alternative CF
animal model for researchers (McCarron et al., 2020).
Preliminary data from this model showed altered function
of the nasal epithelial ion channels that is consistent with the
CF profile (McCarron et al., 2020). Those preliminary nasal PD
investigations were performed as non-recovery procedures due
to rats displaying a heightened sensitivity to fluid in the
airways and respiratory difficulties following the procedure,
meaning that recovery was not possible. The initial nasal PD
assessments in rats were performed in the same manner as for
mice, with the animal hung by the dorsal incisors in a vertical
position (Limberis et al., 2002). This orientation proved to be
problematic, as all nasally delivered solutions collected in the
lungs, resulting in respiratory distress. Other factors limiting
the first nasal PD investigations in rats included the poor
integrity of the existing nasal PD fluid delivery perfusion
tubing arrangement. Therefore, the nasal PD measurement
technique in rats needed to be optimised to achieve improved
reliability so that the effect of treatments such as airway gene-
addition therapy could be assessed.
In this study we firstly optimised the technique of performing
nasal PD measurements in rats to test ion channel function. We
then investigated whether a single dose of our LV-V5-CFTR
vector delivered after conditioning with LPC recovers CFTR
function in the nasal epithelium of CF KO rats.
METHODS
Animals
This project was conducted under the approval from the
University of Adelaide Animal Ethics Committee (M-2017-
056). All rats were maintained in conventional cages with a
12-h light/dark cycle. Food and water were provided ad
libitum, with all rats receiving a 50:50 mix of normal and high
fat (10%) rodent chow. CF rats received water containing 4.5%
ColonLytley (Dendy Pharmaceuticals, Australia) to minimise CF
related gut obstructions. Female and male CF KO rats (510X
genotype) (McCarron et al., 2020) were used.
Nasal PD
Ion channel function was measured using a newly optimised
nasal PD technique adapted from mouse protocols (Limberis
et al., 2002; Cmielewski et al., 2010) and early CF rat
characterisation studies (McCarron et al., 2020). Rats were
anesthetized with 60–75 mg/kg of a mixture of ketamine
(Ceva, Australia) and medetomidine 0.4 mg/kg (Ilium,
Australia), delivered by intraperitoneal injection. Rats were
then placed on a customised nasal PD platform, in the prone
orientation. Upper incisors were hooked over a wire loop,
resulting in their mouth being open, rather than vertical with
an endotracheal tube as in the initial rat PD method.
Our old PD system was constructed using long thin
polyethylene tubes and cut-down needles sealed with
superglue or silicone sealant where connections were required.
This perfusion tubing had poor integrity, with bubbles and
blockages regularly interrupting the continuous electrical
circuit, leading to erroneous PD readings. New perfusion lines
(Instech, United States) were made using 25 ga tubing (#BTPE-
25), PinPorts (#PNP3F25) and PinPort connectors (#PNP3M-50)
designed for minimal dead space volumes, as well as three-way
tubing connectors (#SCY25), to create an enclosed system that
prevented bubble formation. A micropositioner provided fine tip
positioning and firmly held the nasal cannula in place, thus
limiting movement while the cannula sat in the nose. Excess
perfusion fluid coming out of the nasal cavity and/or mouth was
absorbed with tissue. A 15 ml centrifuge tube was placed under
the neck to create a slight downwards bend of the head and nose
tip to help prevent fluid from moving distally and entering the
trachea. The cannula was inserted 4–7 mm into the nasal cavity,
based on identification of the location of nasal respiratory
epithelium using dissected rat heads (not shown) and
comparison to rat nasal diagrams (Mery et al., 1994). The
reference electrode inserted subcutaneously into the abdomen,
and connected to calomel electrodes (Hg2Cl2 in 3 M KCl, Cole-
Parmer Instruments, United States) (Limberis et al., 2002;
Cmielewski et al., 2010).
The optimised nasal PD method was then tested in wild-type
(WT) and CF KO rats. PD data was recorded using a optically
isolated high-impedance millivolt meter (ISOMIL, World
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Precision Instruments) connected to an eight channel Powerlab,
combined with Labchart software (Version 8, ADInstruments).
The nasal cavity was perfused at a rate of 10 μL/min with the
following solutions: 1) normal Krebs-Ringer buffer (basal KRB),
2) KRB containing 100 µm amiloride, 3) low chloride KRB with
100 µm amiloride, and 4) low chloride KRB containing 100 µm of
amiloride and 100 µm of isoproterenol. Each solution was
perfused for 10–15 min until a plateau of 1–2 min was
obtained. The change in PD (ΔPD) was calculated by
subtracting the PD values at the plateau for each different
solution. PD traces were rejected if they were non-responders.
Vector Production
This study employed a third generation, HIV-1 derived, VSV-G
pseudotyped, CFTR gene vector with a V5 epitope tag located on
the N-terminus. Gene expression was driven by the EF1α
promoter (CCL-EF1α-V5-CFTR) The vector will be referred to
as LV-V5-CFTR. LV vector was produced as described previously
(Rout-Pitt et al., 2018). Briefly, HEK 293T cells seeded in 10-layer
cell factories were transiently transfected using a five-plasmid
system and calcium phosphate co-precipitation. Two days post-
transfection the vector supernatant was harvested and purified by
anion exchange chromatography, followed by
ultracentrifugation. Vector was formulated in 0.1% heat-
inactivated rat serum in 0.9% saline.
Vector Titre
The titre of the LV-V5-CFTR vector was determined by flow
cytometric detection of V5 expressing-cells. HEK 293 T cells
were transduced with a serially diluted (1:2,500–1:320,000)
vector followed by collection 72 h post-transduction. Cells
were fixed in 4% paraformaldehyde, permeabilized with ice
cold 90% methanol, and resuspended to a concentration of 1 ×
106 cell/mL for staining. Primary antibody rabbit anti-V5 Tag
(#13202, Cell Signaling Technologies, United States) and
secondary antibody goat anti-rabbit IgG (Alexa Fluor 568)
(a11011, Invitrogen, United States of America) were added to
the cells separately for 1 h and 30 min respectively at room
temperature. Cells were washed between antibody staining
and after, then resuspended in PBS. Cells were analysed using
flow cytometry (LSRFortessaTM; Becton Dickinson,
United States). The proportion of V5-positive cells was
used to calculate functional titre in transducing units per
ml (TU/mL). A titre of 8 × 106 TU/ml was used for rat nasal
dosing.
Nasal Vector Dosing
Rats were anaesthetised as described above. Lubricating eye
ointment was placed onto the eyes to minimise drying. Rats
were placed on a heating mat for the duration of the procedure
and recovery period. Instillations were performed into the
right nostril using a micropipette and thin gel tip (No:
5,242,956.003, Microloader, Eppendorf, Germany). Airway
conditioning was performed with 2 × 5 µL aliquots of 0.3%
LPC (#L4129 Sigma, United States), delivered 1 h prior to 2 ×
10 µl aliquots of LV-V5-CFTR vector. Anaesthesia was
reversed using 1 mg/kg atipamezole (Jurox, Australia).
Baseline PD was performed at least one week before LV-
CFTR delivery on the untreated nostril. One week after LV-
CFTR delivery, PD measurement was performed on the treated
FIGURE 1 | Nasal PDmeasurements fromWT and CF KO rats. Nasal PDmeasurements in WT and CF KO rats for (A) basal KRB (B) the ΔPDNa (C) ΔPDCl and (D)
ΔPDIso (n  6–10 animals/group; **p ≤ 0.01, ***p ≤ 0.001, unpaired t-test). Data represented as the mean −/+ SEM.
Frontiers in Pharmacology | www.frontiersin.org May 2021 | Volume 12 | Article 6822993
Reyne et al. Gene Therapy Recovers CFTR Function
nostril. All PD tracings were interpreted by an experienced
assessor blinded to the treatment.
Immunohistochemistry
Rats were humanely killed by intracardiac sodium pentobarbital
overdose (300mg/kg) while under anaesthetic. To examine the nasal
passageways the heads were collected and immersion fixed in 10%
neutral buffered formalin followed by decalcification in 25% EDTA
(pH 7.4) for 7–14 days at 37°C. Heads were cut, paraffin-embedded,
sectioned at 5–7 μm, and deparaffinised using standard histological
procedures. Antigen retrieval was performed using 10mM sodium
citrate buffer (pH 6.0) for 20 min followed by permeabilisation in
0.3% Triton-X 100 in PBS for 10 min. Sections were blocked for 1 h
at room temperature with 1% BSA in PBS and then incubated with
goat anti-V5 primary antibody (1:300) (ab95038, Abcam) in 1%BSA
+ 0.05% Tween overnight at 4°C. Sections were rinsed and incubated
in donkey anti-goat (IgG) Alexa Fluor 568 (1:400) (ab175704,
Abcam) made in 1% BSA and 0.1% Tween incubated at room
temperature for 1 h. Samples were washed with 0.1% Tween-PBS,
counterstained with DAPI for approximately 10min, washed, and
mounted with ProLongTM Diamond antifade mounting media
(#P36961, Life Technologies, United States). Slides were visualised
FIGURE 2 |Representative nasal PD tracing ofWT, CF KO and treated CF KO rat. When compared toWT, CF KO rats demonstrate classic CF electrophysiological
defects in nasal respiratory epithelium. Treated CF KO rats demonstrate a PD trace showing the corrected bioelectrical defect.
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for the presence of V5 staining using an Olympus BX51 Research
grade optical microscope DIC with AnalySIS Life Sciences software.
Statistical Analysis
Statistical analysis was performed using Graphpad Prism V9.0
(GraphPad Software Inc.). Statistical significance was set at p ≤
0.05 and a statistical power greater than 0.80 was required. Paired
t-tests were used to compare the treated and untreated nostril in
each rat. In text values are reported as mean ±SD.
RESULTS
Nasal PD Assessment Was Optimized in
Rats
To improve nasal PD assessments in rats we developed an
optimised testing method. In the preliminary nasal PD studies
(McCarron et al., 2020), rats readily inhaled the nasally
delivered solutions into the lung, often leading to
respiratory distress. This was a critical limitation, as rats
could not be recovered from anaesthesia following the
procedure. Several measures aimed at reducing that original
procedure-associated complication were successfully trialed,
including placing the rats in their naturally prone position, and
absorbing the excess fluid from the nasal cavity. Using tubing
with a smaller bore diameter reduced the volume of fluid in the
system and enabled perfusion fluids to be rapidly changed,
without excessive fluid delivery to the nose. Subsequently, rats
did not show signs of respiratory distress and no mortality was
associated with the nasal PD procedures.
Confirmation of WT and CF Rat Nasal PD
Profiles
This study provides an improved characterisation of the airway
bioelectric profile in our CF KO rats (McCarron et al., 2020),
with the greater power revealing that there was a statistically
significant difference in the isoproterenol response between
WT and KO CF rats (p ≤ 0.01, Figure 1). Under basal
conditions, CF KO rats demonstrated a significant negative
PD when compared to the WT rats. When the ENaC inhibitor
amiloride was perfused, CF KO rats exhibited a more enhanced
depolarisation response than WT rats, indicating increased
luminal retention of sodium. Low chloride and isoproterenol
solutions produced either no response or a small depolarisation
in CF (whereas a hyperpolarisation was observed in WT
rats) suggesting the absence of CFTR-mediated chloride
transport.
Ion channel function can be restored in
nasal epithelium of CF KO rats after
treatment with LV-V5-CFTR
Figure 2 depicts representative PD traces fromWT, CF KO and a
treated CF KO rat, showing the correction of the bioelectrical in
the treated CF KO rat.
FIGURE 3 | Pre-treatment and post-treatment nasal PD results following LV-V5-CFTR vector delivery to nasal epithelium of CF KO rats. Nasal PDmeasurements in
CF KO rats for (A) basal KRB (B) ΔPDNa (C) ΔPDCl, and (D) ΔPDIso. Dot/dash line indicates the WT average (*p ≤ 0.05, **p ≤ 0.01, paired t-test; n  14–16). Data
represented as the mean with −/+ SEM.
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Seven days after delivery of LV-V5-CFTR to CF KO rats (n 
16), the basal KRB (−24.2 ± 7.8 mV) response exhibited a
significantly smaller depolarisation compared to pre-treatment
(−32.8 ± 7.9 mV), which was closer to a WT response (p ≤ 0.05)
(Figure 3). The amiloride response in treated (13.0 ± 6.7 mV) CF
KO rats had an improvement of 51% toward the WT value when
compared to the pre-treatment (18.2 ± 5.3 mV) (p ≤ 0.05).
Treated CF KO rats also showed a more negative low chloride
response (0.6 ± 4.7 mV), which was significantly different from
the pre-treatment response (5.9 ± 3.6 mV) (p ≤ 0.01) (Figure 3).
The isoproterenol response did not reach statistical significance
between pre- and post-LV treatment (0.08 ± 3.6 and −1.5 ±
4.4 mV respectively).
Immunostaining with an anti-V5 antibody demonstrated the
presence of the transgene in the right side (treated) of the nasal
epithelium one week post-delivery, whereas no staining was
observed in the left nostril (untreated). V5 positive staining
was detected in the ciliated cells of the nasal epithelium
(Figure 4).
DISCUSSION
Nasal PD measurement methods have been developed for use in
mice, ferrets and pigs, and enable reliable repeated measurements
in the same animal with low procedure-associated mortality
(Beka and Leal, 2018; Kaza et al., 2017; Salinas et al., 2004).
We have demonstrated that our newly optimised technique and
equipment for conducting electrophysical measurements, can
provide a reliable tool for evaluating airway gene therapy
effects in CF rat nasal airways. The nasal PD baseline data
collected from WT and CF KO rats confirmed that the CF
KO rat displays a bioelectrical defect consistent with the CF
profile (McCarron et al., 2020).
The nasal PD response to the low chloride gradient is used to
both discriminate non-CF from CF animals (Figure 2), and more
commonly to assess the response to therapeutics in vivo (Leonard
et al., 2012). It has been suggested that a relatively small number
of gene corrected airway cells (10%) can restore transepithelial
chloride function to therapeutically significant levels, potentially
providing dramatic improvements in pulmonary function
(Johnson et al., 1992; Marquez Loza et al., 2019). Moreover,
those CF patients with ‘mild’ mutations and residual CFTR
function have less severe lung disease (Griesenbach et al.,
2008) indicating that not all cells are required to be corrected.
Our previous CFmouse study showed a 12–54% correction in PD
towards WT CFTR function as assessed by chloride transport
(Cmielewski et al., 2014), and in this present rat study, a mean of
46% correction was observed. The isoproterenol response did not
reach statistical significance in this study, however larger studies
or a higher level of correction may provide sufficient power to
detect a difference. Importantly, this study showed for the first
time that a single delivery of LV-V5-CFTR could achieve in vivo
correction of nasal airway epithelium ion transport in a CF KO
rat model.
CF epithelial ion transport is characterised by a greater
hyperpolarisation (more negative) measurement of basal KRB
due to the increased activity of ENaC, a large depolarisation in the
presence of a sodium channel blocker, and a small or absent
response to low chloride and isoproterenol solutions. Gene
therapy efforts have focused on the correction of chloride
function and some suggest that the direct interaction between
CFTR and ENaC should be normalised for therapeutic outcomes
(Johnson et al., 1995). Johnson et al. indicated with in vitro studies
using ALI cultures that a majority of the cell monolayer is
required to be expressing CFTR for ENaC transport to be
corrected (Johnson et al., 1995), while another in vitro study
suggested that 60% of ciliated cells may be enough to normalise
sodium ion transport (Zhang et al., 2009). We noted there was a
statistically significant mean correction of 51% towardsWT in the
FIGURE 4 | Immunohistochemical detection of V5-CFTR in the rat nasal
epithelium. (A,B) V5 IHC enables localisation of CFTR (red) in the right nostril
(treated) one week after delivery of LV-V5-CFTR. (C) No staining was
observed on the left (untreated) side of the rat nose. Scale bar 20 μm.
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amiloride response after LV vector treatment in CF rats. This may
suggest that the sodium hyperabsorption defect present in CF rats
may have been improved, however, further studies utilising
Ussing chamber assessments are needed to link altered sodium
absorption to the insertion of a functioning CFTR channel.
The HIV-1 virus-based vector system has been extensively
modified to improve safety and efficacy for use in gene therapy
(Milone and O’Doherty, 2018). While our previous CFTR
airway gene-addition studies employed second generation
LV vectors with internal viral promoters (e.g., SV40), for
the first time this study used a third generation vector with
an EF1α promoter, tagged with V5 for immunodetection. For
these reasons this vector system is more appropriate for
clinical application than those used in our previous mouse
studies (Cmielewski et al., 2014). Importantly, the use of the
V5 tag did not interfere with functionality of the CFTR
protein, as demonstrated by significant correction of
bioelectric defect as measured by nasal PD.
This study had some limitations. Firstly, it was designed to be a
short-term assessment and did not investigate the ability to
achieve long term correction of nasal ion transport. For gene
therapy to be successful the expression of CFTR needs to be
permanent and life long, and this study sets the stage for future
long-term investigations in CF rats. Assessing persistence of gene
expression over long durations in CF rats and the ability to re-
dose if correction wanes are all next steps. Secondly, the total
number of CFTR transduced cells was not quantified here, but in
future studies where histological outcomes are not required the
nasal epithelium could be removed, the cells dissociated and the
V5 positive cell population quantified by flow cytometry. CFTR
protein expression could also be further examined by Western
blot. Thirdly, the use of a non-CFTR LV vector control could be
employed to verify that the delivered CFTR gene was responsible
for the effects observed here. Lastly, a CFTR inhibitor might be
used to further discriminate CFTR function, although one study
suggests that CFTRinh-172 does not have an effect in rats
(Dreano et al., 2019).
In summary, using our optimised PD protocols we showed
successful correction of the bioelectrical defect in our newly
established CF KO rat model for the first time. Future studies
will focus on assessing long-term CFTR correction, to help
validate the effectiveness of this LV vector for translation to
the clinic as a potential and fundamental treatment for CF lung
disease.
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